Aegis Capital reiterated coverage on Oramed Pharmaceuticals with a new price target
$ORMP
Biotechnology: Pharmaceutical Preparations
Health Care
Aegis Capital reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $20.00 from $12.00 previously